A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

NCT01245816 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Familial Adenomatous Polyposis

Interventions

DRUG: Eflornithine plus Sulindac
DRUG: Eflornithine plus Placebo
DRUG: Sulindac plus Placebo

Sponsor

Cancer Prevention Pharmaceuticals, Inc.